<SEC-DOCUMENT>0001193125-20-150909.txt : 20200526
<SEC-HEADER>0001193125-20-150909.hdr.sgml : 20200526
<ACCEPTANCE-DATETIME>20200526082833
ACCESSION NUMBER:		0001193125-20-150909
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20200526
DATE AS OF CHANGE:		20200526
EFFECTIVENESS DATE:		20200526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16174
		FILM NUMBER:		20908209

	BUSINESS ADDRESS:	
		STREET 1:		5 BAZEL ST
		STREET 2:		P O B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
		BUSINESS PHONE:		9729267267

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		5 BAZEL ST PO B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d916269ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Proxy
Statement Pursuant to Section&nbsp;14(a) of </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Filed by the Registrant&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9746;</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Filed by a Party other than the Registrant&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preliminary Proxy Statement</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2"><B>Confidential, For Use of the Commission Only (as permitted by Rule <FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Definitive Proxy Statement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Definitive Additional Materials</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>TEVA PHARMACEUTICAL INDUSTRIES LIMITED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if
other than the Registrant) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Fee computed on table below per Exchange Act Rules <FONT STYLE="white-space:nowrap">14a-6(i)</FONT> (1)&nbsp;and <FONT STYLE="white-space:nowrap">0-11.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title of each class of securities to which transaction applies:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Aggregate number of securities to which transaction applies:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11</FONT> (set forth the amount on which the filing fee is calculated and state how it was
determined):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(4)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Proposed maximum aggregate value of transaction:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(5)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Total fee paid:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Amount Previously Paid:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form, Schedule or Registration Statement No.:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Filing Party:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(4)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Date Filed:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDITIONAL INFORMATION REGARDING THE ANNUAL MEETING OF STOCKHOLDERS TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BE HELD ON TUESDAY, JUNE&nbsp;9, 2020 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
April&nbsp;22, 2020, Teva Pharmaceutical Industries Ltd. (the &#147;Company&#148;) filed a definitive proxy statement with the Securities and Exchange Commission regarding its Annual Meeting of Shareholders (the &#147;Annual Meeting&#148;) to be
held on Tuesday, June&nbsp;9, 2020. The following information supplements and relates to that proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;26, 2020, the Company issued a
press release announcing that the Annual Meeting will be changed from an <FONT STYLE="white-space:nowrap">in-person</FONT> meeting to a virtual meeting, conducted solely via live webcast, providing information as to how shareholders can attend and
participate in the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as specifically revised by the information contained herein, this supplement does not revise or update any of
the other information set forth in the proxy statement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLEASE READ THESE MATERIALS CAREFULLY IN CONJUNCTION WITH THE PROXY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT AND OTHER PROXY MATERIALS </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g916269g81n53.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:-80pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>TEVA ANNOUNCES VIRTUAL 2020 ANNUAL MEETING OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL"><B>Tel Aviv, Israel, May&nbsp;</B><B>26</B><B>, 2020</B> &#150; Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA)
(&#147;Teva&#148;), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of the current COVID-19 pandemic, the format of its 2020 Annual Meeting of Shareholders has been
changed to a virtual meeting. Teva&#146;s 2020 Annual Meeting will be held on Tuesday, June 9, 2020 at 4:30 p.m., Israel time (9:30 a.m., New York time), as previously announced. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL">Shareholders will not be able to physically attend the 2020 Annual Meeting. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL">To participate in the virtual 2020 Annual Meeting, holders of Teva&#146;s American Depositary Shares (&#147;ADSs&#148;) and ordinary
shares should visit <U>www.meetingcenter.io/218625112</U> and, when prompted, enter their control number (see below). The meeting password is TEVA2020. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL"><B><I>Holders of ADSs </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL">Holders of ADSs as of the close of business on April&nbsp;30, 2020 (the &#147;Record Date&#148;) will be able to participate in the
virtual 2020 Annual Meeting and ask questions through the online meeting platform. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL">Record holders of ADSs should enter the
15-digit control number on the proxy card or Notice of Internet Availability of Proxy Materials previously received. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL">Beneficial
holders of ADSs that are registered in the name of a broker, bank or other agent must register in advance to participate in the virtual 2020 Annual Meeting and ask questions through the online meeting platform. To register, beneficial holders of
ADSs must submit proof of ownership reflecting the number of ADSs beneficially owned as of the Record Date, along with their name and email address, to Computershare at <U>legalproxy@computershare.com</U>. Requests for registration must be labeled
as &#147;TEVA MEETING REQUEST&#148; and must be received no later than Friday, June 5, 2020 at 9:30 a.m., New York time. Beneficial holders of ADSs will then receive a confirmation of registration with a 15-digit control number by email from
Computershare. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL">Holders of Teva&#146;s ADSs may not vote through the online meeting platform. To vote, holders of ADSs should
follow the instructions set forth in Teva&#146;s Proxy Statement filed with the Securities and Exchange Commission on April 22, 2020. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL"><B><I>Holders of Ordinary Shares </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL">Holders of Teva&#146;s ordinary shares as of the Record Date will be able to participate in the virtual 2020 Annual Meeting, vote their
shares and ask questions through the online meeting platform. If a holder of Teva&#146;s ordinary shares would like to appoint another person to act as his/her authorized proxy, such proxy must be submitted along with an email address to Teva at
<U>TevaAGM2020@tevapharm.com</U>, must be labeled as &#147;TEVA MEETING REQUEST&#148; and must be received no later than June&nbsp;5, 2020 at 4:30 p.m., Israel time. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL">Record holders of ordinary shares must enter a control number to access the online
meeting platform. The control number will consist of the holder&#146;s Israeli identification number or Israeli company registration number as it appears in Teva&#146;s share register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL">Holders of ordinary shares registered pursuant to Section&nbsp;177(1) of the Israeli Companies Law, 5759-1999 whose shares are held
through a nominee company (&#147;Non-Registered Holders&#148;) must register in advance to participate in the virtual 2020 Annual Meeting, vote their shares and ask questions through the online meeting platform. To register, Non-Registered Holders
must submit proof of ownership (including Israeli identification number or company registration number) reflecting the number of ordinary shares beneficially owned as of the Record Date, along with their name and email address, to Teva at
<U>TevaAGM2020@tevapharm.com</U>. Requests for registration must be labeled as &#147;TEVA MEETING REQUEST&#148; and must be received no later than June&nbsp;5, 2020 at 4:30 p.m., Israel time. Such Non-Registered Holders will then be able to use
their Israeli identification number or company registration number as it appears on the proof of ownership provided to Teva as the control number to access the online platform. If a Non-Registered Holder would like to appoint another person to act
as his/her authorized proxy, such proxy must be submitted to Teva along with the proof of ownership. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL"><B><I>Additional information
for holders of ordinary shares and ADSs on how to participate </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">Access the meeting platform at <U>www.meetingcenter.io/218625112</U> and enter the meeting password TEVA2020 and your
15-digit control number (for holders of ADSs) or Israeli identification number or company registration number (for holders of ordinary shares) beginning on Tuesday, June 9, 2020 at 4:15 p.m., Israel time. </P></TD>
<TD WIDTH="21%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">To submit a question before or during the meeting, visit <U>www.meetingcenter.io/218625112</U> with your control number and
click on the messages icon to submit your question.</P></TD>
<TD WIDTH="21%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt">If you encounter any technical difficulties with the meeting platform on the date of the virtual 2020 Annual Meeting,
technical support will be available during this time and will remain available until the virtual 2020 Annual Meeting has ended. </P></TD>
<TD WIDTH="21%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:12pt"><B>Whether or not you plan to attend Teva&#146;s virtual 2020 Annual Meeting, we urge you to vote and submit your proxy in
advance by one of the methods described in the proxy materials for the 2020 Annual Meeting.</B> </P></TD>
<TD WIDTH="21%">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL"><B>About Teva </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL">Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people&#146;s lives
for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL">
products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at http://www.tevapharm.com.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; margin-right:21%; font-size:12pt; font-family:ARIAL">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,
which are based on management&#146;s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that
expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to our business and operations in general, including uncertainty regarding the magnitude, duration,
and geographic reach of the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; and other factors discussed in this press release, in our Quarterly Report on
Form 10-Q for the first quarter of 2020 and in our Annual Report on Form 10-K for the year ended December 31, 2019, including in the sections captioned &#147;Risk Factors&#148; and &#147;Forward Looking Statements.&#148; Forward-looking statements
speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are
cautioned not to put undue reliance on these forward-looking statements. </P> <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g916269sp147.jpg" ALT="LOGO">
 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g916269g81n53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g916269g81n53.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #V L8# 2(  A$! Q$!_\0
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M*L :\NM7QE/=V^2_R/AJV?<38"7+CI./FX1M]_+8^MX_VYMZY_X0G'_<6_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9H<91J14HO1A1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2=
M:6B@!NT'/%9NO>&=+\3:?+8:I8PWUI(,-%,@8?4>A]Q6I12:35F3**DFI*Z9
M\H?%#]DR>S\S4/!\AN(<EFTV=_G7VC8]1[,<^YKYZN+&ZTN\EM;N"2UN8F*O
M%*I5E8=B#7Z8M&&KA_B-\(/#OQ(M<:E;>5>J,1WT&%E7V)_B'L?PP>:\'%95
M"I>5'1]NA\3F'#5.M^\PGNR[=/\ @'P=;WS1_+(,CIQU%:<,BR1G:<UT7Q*^
M#.O?#6[=[J%KK2RV(M0A7Y#SP'Y^5O8\>A-<7$QCPRD@U\A5HRI2<9JS/B>6
MKA9NG7C9HW5[5(M4+6^#D"3Y3_>[5H+]<UR2T/2IR4EH2Q_=JPO2J\?W:L+T
MJ'L=<2=:EC[5$M2Q]JS.FGL3+5F+[HJLM68ONBID=*W)8^AJPOW:KQ]#5A?N
MTCH6Y87[H^E/6F+]T?2GK0;(N)]VGKUIB?=IZ]:F6QO$^C/A/_R3_2O^VO\
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M16U^^Q]\,V.:XO2OB-%K7CR;0K.))+6"%F>ZSUD4@$+[<GGU_7RS]J#XY?\
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M[:_^C7HK]8P/^ZTO\,?R1]+2_AQ]$==24M%=IJ-VT;?7^5.HH 3;1M'I2T4
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MO^VO_HUZ*_6,#_NM+_#'\D?2TOX<?1'74445VFH4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 E<]X\\/#Q)X9OK,*#+LWQ>TB\K^9X_&NBI*SJ4XU8.$MF*45)-,^05C.X
MCD8]14E=5\2]!_L'Q9=*JXAN?])3T&XDD?@<_I7*U^2UJ;HU94I;IGS,X\DG
M'L?1GPE_Y)_I7_;7_P!&O11\)?\ DG^E?]M?_1KT5^I8+_=:7^%?D?14?X<?
M1'7T445V&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M% 'E_P <
M-%^U:/::D@RUM)L?UVMC^N/SKQ;;CZU]2^)-*36M#OK)U#":(J ?[W8_@<'\
M*^8&B>%RC@JZG:RGJ"*_/\^P_)755?:7XH\;%PY9\W<^A?A/_P D_P!*_P"V
MO_HUZ*7X4_\ (@Z7_P!M?_1KT5]G@O\ =:7^%?D>I2_AQ]$=;1117::A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% #6 KYR^(FEC1_&&H0KDK(
M_G+GT;G^>ZOHXC->0?'+2@EUINHJ/F<- _X<K_-J^>SRC[3"\ZWBSCQ4>:G?
ML=G\*?\ D0=+_P"VO_HUZ*/A3_R(.E_]M?\ T:]%>K@O]UI?X5^1T4OX<?1'
M6T445V&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PWQ>T_[
M9X/N)-NYK>1)1ZCG:?T8UW-9GB2Q_M+0=0M@NYI8'0?4@X_6N7%4_:T)P[IF
M=1<T&C%^%/\ R(.E_P#;7_T:]%+\*_\ D0]+P,?ZW_T:]%3@M,+27]U?D%+^
M''T1UE%%%=AH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(R[
J@1ZT44 4M%T>#0=-CLK8L88RS#>1GYF+'H!W)HHHJ8Q44HQV0EIHC__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g916269sp147.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g916269sp147.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H IZEJMEH]LMQ?3>3$S[ VTMS@G' /H:B<
MXP5Y$3G&"O(RO^$X\.?]!'_R#)_\36?UBGW,_K%+N'_"<>'/^@C_ .09/_B:
M/K%/N'UBEW#_ (3CPY_T$?\ R#)_\31]8I]P^L4NX?\ "<>'/^@C_P"09/\
MXFCZQ3[A]8I=P_X3CPY_T$?_ "#)_P#$T?6*?</K%+N'_"<>'/\ H(_^09/_
M (FCZQ3[A]8I=P_X3CPY_P!!'_R#)_\ $T?6*?</K%+N'_"<>'/^@C_Y!D_^
M)H^L4^X?6*7</^$X\.?]!'_R#)_\31]8I]P^L4NX?\)QX<_Z"/\ Y!D_^)H^
ML4^X?6*7</\ A./#G_01_P#(,G_Q-'UBGW#ZQ2[A_P )QX<_Z"/_ )!D_P#B
M:/K%/N'UBEW#_A./#G_01_\ (,G_ ,31]8I]P^L4NX?\)QX<_P"@C_Y!D_\
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M2 2HXD9A+P"=ORXP,\Y.?;'-4XI.273^OZ_04*C:C=;K^OZ_,W:@W"@ H *
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MV5FB/E81I5&W>F1C@<9ZY/J>@Q3Y;2Y?-K\@5;W>=K9)_BU^AU2DE06 !QR
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M.SO+N;6+JW9H9;2)>)(XRI1\_<))(8XZXQBDM8W9I=\]NGY?\/\ UN:=(L*
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%E:6KRO;VT,+RG=(T:!2Y]3CK2V5AV2=^I/0,* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MK(KA#$UM()"2"1A-NX\ ]!VHM?8IU(J]R,>*--$UQ$XN8V@F$.#;.=[$9 4
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M#[0P7RRX&<<'(X[D 4EM?U_#<.?WN6W9??:WYDEOK^F7.WRKALLZHH:)U)+
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MIM.YE*E%JW827PCITUMY#M*P&S:6"-@KNP<,I!^\>H-+:W]=$OT&Z:=[]?\
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MXW(*Q;VW-MXSR?4FA.RMZ+Y+8KD7-S?/YO<U*184 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MUU-R*030I*H8!U# ,,$9]1VH:L[%Q?,DT/I%!0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % %34]/BU73IK*=G6*4 $H0",'/?Z4+1I]
MM127-%Q?70SXO"]I'J)OC/.\QF$W\"C(# <*HSPQY// YII\JLO/\3-TDW?T
M_ I?\('I1:X9I)W,S!OFV':0Q;/*_-R3][=QQ23LDET_RL)T8MMOK_G?]#5T
M[0[;3)O-A9BWDB'&U%7 8MG:J@ Y8]*KFW_KI8J--1M;I^NIIU)H% !0 4 %
M !0 4 % !0 4 % $5S;I=VDUM)D)*A1L=<$8I-75AIV=S-G\.VLUPDAFG1 L
M:O$K +((SE-W&>#Z$55]6_._S,?9*R7E;Y%:;P?830+$TUP%6-8^J'(#EAD%
M2#R>XQ2_X'X*PW33_'\7?] /A"Q^R_9EN+E8O)2$J"A#!&W*2"I!ZGCH0>13
M;OO_ %I87LDE9>GXW')X3L([-;599_+6,1CE<X$F_P!/7]*?,[W]/PT$J,5'
ME]?QW_X!9O\ 08-0OA<R7$Z JB/$A7:X5MPSD$]?0BIC[KN7.'/I_6I2_P"$
M*TG;-&58Q2N'9/+C'1MV-P7<1GU)IIV27;_)K]272BVWW_S3_0E;PI8O>QW;
MR2/,J*A=TC=FP, [BA(/NI%)ZW7?]=/ZZ#]E&\7V_1W_ *ZFO9VJ65E!:QEC
M'#&L:ENI &.:J4G*3DQP@H145T)JDL* "@ H * "@"IJ6GQZG9/:RL51R,D(
MC]/9U8?I2M<35U8AM=%M+(6:PAA'9HRQ)QM!/5NG7K^9JFVVW\OZ_KH1&G&*
M2737^OQ&V.C"Q2Y0WMQ<"X)+><$SD]3E5!/IR3P!4R5X<A45RSYKD":"9K&Q
MMKZZD:.V1 88]HC=DZ-G;N[ \$5<GS2<GU_7<B-/EBH7T7Z;$0\+VUJK)9/*
MJ2RPM(LLSN%6,@@+G/H!_G%"D[J_=O\  /9))\O:WRO_ )7+5UH%O=ZHM^\\
MZNI4^6I7:2N<<XW#KV(SWJ5I?^MU8J4.9I_UH[E2/PC:1P-&MY=YRA#$H2NW
M.!C;ANIY8$^]._\ 7RM_5B?9+77^KW_J]R\VC)_9,6FQ7EQ# B;"5V%G7&,$
MLI_3%$O>>I2CRJR?]?D5E\,6:7HN$GG0*,+'E2J_)L[J3T[$X]J&V[WZW_$2
MII-6Z6_ A7P=I\=IY$4LL1\PR,\:1KN)7;RNS9T]%H;N)4E';]/^&-VWA6VM
MXH$+%(U"#<<G &.31)\SNRXQ4(J*Z$E(H* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
F * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
